Literature DB >> 18922105

FLT3 inhibitors for the treatment of autoimmune disease.

Katharine A Whartenby1, Donald Small, Peter A Calabresi.   

Abstract

BACKGROUND: Autoimmune diseases encompass a broad range of illnesses with a variety of underlying causes, some of which are known and some of which remain elusive.
OBJECTIVE: The focus of this review will be on describing the development of a new type of therapy that could potentially treat T cell-mediated autoimmune diseases. Unlike traditional therapies, which have primarily focused on suppressing T cells directly, targeting the step of antigen presentation may allow a less toxic therapy in which autoimmunity is lessened without compromising the entire immune system. This review will outline the science behind the development of the therapy, the roles of dendritic cells in generating autoimmune disease, and the function of the FLT3 receptor in this process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922105      PMCID: PMC4882767          DOI: 10.1517/13543784.17.11.1685

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  74 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis.

Authors:  R Stanislaus; A K Singh; I Singh
Journal:  J Neurosci Res       Date:  2001-10-15       Impact factor: 4.164

3.  Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.

Authors:  Eileen J McMahon; Samantha L Bailey; Carol Vanderlugt Castenada; Hanspeter Waldner; Stephen D Miller
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

4.  Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Authors:  D Auclair; D Miller; V Yatsula; W Pickett; C Carter; Y Chang; X Zhang; D Wilkie; A Burd; H Shi; S Rocks; R Gedrich; L Abriola; H Vasavada; M Lynch; J Dumas; P A Trail; S M Wilhelm
Journal:  Leukemia       Date:  2007-01-04       Impact factor: 11.528

5.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.

Authors:  W Matthews; C T Jordan; G W Wiegand; D Pardoll; I R Lemischka
Journal:  Cell       Date:  1991-06-28       Impact factor: 41.582

6.  Inhibition of natural type I IFN-producing and dendritic cell development by a small molecule receptor tyrosine kinase inhibitor with Flt3 affinity.

Authors:  Roxane Tussiwand; Nobuyuki Onai; Luca Mazzucchelli; Markus G Manz
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

7.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

8.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

9.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

10.  A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Authors:  Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

View more
  9 in total

Review 1.  The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues.

Authors:  K Sanjana P Devi; Niroshana Anandasabapathy
Journal:  Semin Immunopathol       Date:  2016-11-25       Impact factor: 9.623

2.  Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use.

Authors:  Rami Ayoub; Jamal Jilani; Qais Jarrar; Raad Alani; Chrismawan Ardianto; Khang Wen Goh; Dalia Ali; Said Moshawih
Journal:  Molecules       Date:  2022-05-08       Impact factor: 4.927

3.  Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.

Authors:  Panagiotis Garantziotis; Dimitrios Nikolakis; Stavros Doumas; Eleni Frangou; George Sentis; Anastasia Filia; Antonis Fanouriakis; George Bertsias; Dimitrios T Boumpas
Journal:  Front Immunol       Date:  2022-05-09       Impact factor: 8.786

4.  Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor.

Authors:  Heng-Xiu Yan; Wei-Wei Li; Yan Zhang; Xia-Wei Wei; Li-Xin Fu; Guo-Bo Shen; Tao Yin; Xiu-Ying Li; Hua-Shan Shi; Yang Wan; Qing-Yin Zhang; Jiong Li; Sheng-Yong Yang; Yu-Quan Wei
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

5.  Genetic deficiency of Syk protects mice from autoantibody-induced arthritis.

Authors:  Zoltán Jakus; Edina Simon; Bálint Balázs; Attila Mócsai
Journal:  Arthritis Rheum       Date:  2010-07

6.  Aptamer-based search for correlates of plasma and serum water T2: implications for early metabolic dysregulation and metabolic syndrome.

Authors:  Vipulkumar Patel; Alok K Dwivedi; Sneha Deodhar; Ina Mishra; David P Cistola
Journal:  Biomark Res       Date:  2018-09-17

7.  P. granatum Peel Polysaccharides Ameliorate Imiquimod-Induced Psoriasis-Like Dermatitis in Mice via Suppression of NF-κB and STAT3 Pathways.

Authors:  Haiming Chen; Cheng Wang; Bin Tang; Jingjie Yu; Yue Lu; Junhong Zhang; Yuhong Yan; Hao Deng; Ling Han; Shaoping Li; Chuanjian Lu
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

8.  Transcriptome-wide association study reveals increased neuronal FLT3 expression is associated with Tourette's syndrome.

Authors:  Calwing Liao; Veikko Vuokila; Hélène Catoire; Fulya Akçimen; Jay P Ross; Cynthia V Bourassa; Patrick A Dion; Inge A Meijer; Guy A Rouleau
Journal:  Commun Biol       Date:  2022-03-30

9.  Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

Authors:  K Reiter; H Polzer; C Krupka; A Maiser; B Vick; M Rothenberg-Thurley; K H Metzeler; D Dörfel; H R Salih; G Jung; E Nößner; I Jeremias; W Hiddemann; H Leonhardt; K Spiekermann; M Subklewe; P A Greif
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.